Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon (Q34285416)

1 August 2017

title

Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. (English)

1 reference

1 August 2017

I A Reilly

1

1 reference

1 August 2017

L Roy

series ordinal

2

1 reference

1 August 2017

G A Fitzgerald

series ordinal

3

1 reference

1 August 2017

publication date

1 April 1986

1 reference

1 August 2017

language of work or name

0 references

1 reference

1 August 2017

volume

292

1 reference

1 August 2017

issue

6527

1 reference

1 August 2017

page(s)

1037-1039

1 reference

Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon.

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Estimated rate of prostacyclin secretion into the circulation of normal man

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Role of cold and emotional stress in Raynaud's disease and scleroderma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Estimated rate of thromboxane secretion into the circulation of normal humans

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

The biochemical pharmacology of thromboxane synthase inhibition in man.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Raynaud's disease, Raynaud's phenomenon, and serotonin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340106

Plasma exchange and platelet function in Raynaud's phenomenon

28 October 2018

1 reference

12 December 2020

Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease

1 reference

12 December 2020

Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites

1 reference

12 December 2020

Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma

1 reference

12 December 2020

Monitoring the entry of new platelets into the circulation after ingestion of aspirin

1 reference

12 December 2020

Effects of thromboxane antagonist EP 045 on platelet aggregation

1 reference

12 December 2020

Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease

1 reference

12 December 2020

A thromboxane synthetase inhibitor in Raynaud's phenomenon

1 reference

12 December 2020

Effect of thromboxane synthetase inhibition in Raynaud's phenomenon

1 reference

12 December 2020

Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon

1 reference

12 December 2020

Analysis of urinary metabolites of thromboxane and prostacyclin by negative-ion chemical-ionization gas chromatography/mass spectrometry

1 reference

12 December 2020

Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography--negative-ion chemical ionization mass spectrometry

1 reference

12 December 2020

Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects

1 reference

12 December 2020

10.1136/BMJ.292.6527.1037

Identifiers

DOI

0 references

PMC publication ID

1340106

1 reference

1 August 2017

1 reference